Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: "Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)." Schaeverbeke et al. Joint Bone Spine 2018;95:399-402

Affiliations

• ¹ Rheumatology department, Lapeyronie hospital, Montpellier university hospital center, 34295 Montpellier Cedex 5, France. Electronic address: jd-cohen@chu-montpellier.fr.
• ² French national patient organization against rheumatoid arthritis (ANDAR), 75014 Paris, France.
• ³ BioCube institute, groupe IMT, 37000 Tours, France.
• ⁴ Law and health economics department, faculty of pharmacy, Paris Descartes university, Sorbonne Paris Cité, 4, avenue de l'Observatoire, 75006 Paris, France; Health law institute (Inserm UMR S1145), Paris Descartes university, Sorbonne Paris Cité, 45, rue des Saints-Pères, 75006 Paris, France; Pharmacy department, general agency of equipments and health products (AGEPS), 7, rue du Fer à Moulin, 75005 Paris, France.